Pfizer to sell Viagra in Israel via Internet

This will be the first time a prescription drug is sold on the Internet in Israel, in what the company says is an anti-counterfeiting move.

Pfizer (NYSE: PFE) has announced an unusual marketing ploy in Israel. For the first time, the company will sell its Viagra drug for treating impotence legally and completely officially on the Internet. A doctor's prescription will still be required, but there will be no need to go physically to a pharmacist. This will be the first time a prescription drug is sold in Israeli via the Internet. Internet pharmacies do exist in Israel, but they sell only non-prescription drugs.

Pfizer is taking this step as part of a multi-faceted war against drug counterfeiters, who operate, among other ways, via the Internet, posing as Pfizer representatives. The company fights the counterfeiters both through advertising and through the police, but with limited success. "A survey we carried out found that only 12% of the population was aware that Viagra bought via the Internet was counterfeit. Most people think that it is genuine Viagra, only sold through illegal distribution channels," says Ofra Feinmesser, country manager of Pfizer Pharmaceuticals Israel Ltd.

There can be serious consequences of this. Feinmesser relates how a man who used counterfeit Viagra died recently at Kaplan Hospital in Rehovot. "High levels of iron were found in his blood," she says, "They'll put anything in counterfeit drugs."

How will you ensure that counterfeiters don't copy your website?

"The site is secured as well as Pfizer knows how. It will carry the Ministry of Health's stamp of approval. Doctors will know how to direct patients to the correct site, and our own media campaigns will help, within the limits of legal drug marketing in Israel."

The site www.original-pill.co.il will direct buyers to the Internet pharmacies where they can order original Viagra by scanning or faxing the doctor's prescription.

Published by Globes [online], Israel business news - www.globes-online.com - on February 7, 2010

© Copyright of Globes Publisher Itonut (1983) Ltd. 2010

5 Comments
View comments in rows
Update by email about comments talkback
POST
Comments
Your name
Please insert your name
Content
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

Thanks
You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
MORE FROM GLOBES
Biolight jumps on strong Zacks recommendation

Zacks cites the company for its technology, products, and meeting its targets.

VBL Therapeutics raises $40m in revived Nasdaq IPO

After the fiasco of the failed IPO in August, the drug development company scaled down the offering.

Assuta Hospital Gov't plans taxing private hospitals

The tax is one of the recommendations of the Economic Arrangments bill.

Erez Vigodman Teva boosted by European drug recommendations

Teva's share jumped 4% in Tel Aviv, after climbing 4.9% on Wall Street.

Partner/Orange Partner launches smartphone medical services

The new services includes prescriptions, hospital referrals, and confirmation of illness.

Reuven Krupik Clal Biotech unit PolyHeal nears licensing deal

PolyHeal has signed an MOU with a European drug company for an exclusive global license.

Nasdaq Galmed jumps on FDA hepatitis drug approval

The FDA awarded Fast Track Designation to aramchol for the treatment of Non-Alcoholic Steato-Hepatitis.

artificial sweeteners Weizmann Inst: Sweeteners cause diabetes, obesity

A study found that artificial sweeteners adversely affect intestinal bacteria.

BioCancell share jumps on positive cancer trial results

The clinical trials demonstrated safety and effectiveness of the treatment on high-risk bladder cancer patients.

Trendlines Group set for Toronto IPO

The technological incubators company is raising C$9 at a company value of C$80 million, after money.

Reuven Krupik Clal Biotech sues Hyperion for $200m

Clal Biotechnology alleges Hyperion made "rash and ill-considered" decisions in the Andromeda affair.

pharmaceuticals Clal Biotech: No evidence of misconduct by us

Clal Biotech says documents it was shown by Hyperion do not indicate it committed any misconduct regarding Andromeda.

Soroka Hospital  picture: Eyal Yitzhar Visiting Israel’s wounded at Soroka

Soroka Medical Center in Beersheva, the Israeli hospital closest to Gaza, bears the medical brunt of Operation Protective Edge.

Twitter Facebook Linkedin RSS Newsletters גלובס